Updated Jul 16, 2026
Ng George K has filed 6 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $39K.
George K. Ng is the Chief Executive Officer of Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy oncology drugs. He has also held a similar role at Kintara Therapeutics, Inc.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 3.1K | $1.93 | $6K |
| 2026-06-16 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 2.5K | $2.22 | $5K |
| 2026-06-01 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 2.1K | $2.57 | $5K |
| 2026-05-19 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 1.8K | $2.97 | $5K |
| 2026-05-01 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 2.0K | $2.69 | $5K |
| 2026-04-17 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 1.8K | $2.97 | $5K |
| 2026-04-01 | PCSA | Processa Pharmaceuticals, Inc. | P — Open-market purchase | 2.1K | $2.54 | $5K |
George K. Ng is the Chief Executive Officer of Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy oncology drugs. He has also held a similar role at Kintara Therapeutics, Inc.…
6 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 7 open-market purchases ($39K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ng George K profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.